Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
-
Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time Atlanta, GA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
-
Atlanta, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and...
-
Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
-
Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
-
Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
-
Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
-
Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
-
Conference Presentation to Include Updates on Three Ongoing Phase 2 Clinical Trials for COVID-19 and Cancer Atlanta, GA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...
-
Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...